NASDAQ · NVCT
Healthcare · Biotechnology
$21.87
Down-$0.97 (-4.44%)
Updated Sep 17, 2026, 5:30 PM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
NVCT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning NVCT.
NVCT research
Company profile and research snapshot.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 6, 2026 | Roth Capital | Buy | — |
| Jun 22, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 12, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 4, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Jun 30, 2026
Nuvectis intends to use the net proceeds from the offering to continue to advance the development programs of NXP100, NXP200, and NXP900 or any future product candidate, hiring of additional personnel, capital
Benzinga · Jun 29, 2026
Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology, today announced
Benzinga · Feb 13, 2026
-SEC Filing
Yahoo · Feb 11, 2026
FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the year ended December 31, 2025 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “20
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NVCT.
